BR0313511A - enos mutantes úteis para terapia de genes - Google Patents

enos mutantes úteis para terapia de genes

Info

Publication number
BR0313511A
BR0313511A BRPI0313511-0A BR0313511A BR0313511A BR 0313511 A BR0313511 A BR 0313511A BR 0313511 A BR0313511 A BR 0313511A BR 0313511 A BR0313511 A BR 0313511A
Authority
BR
Brazil
Prior art keywords
mutant
enos
polypeptides
gene therapy
amino acid
Prior art date
Application number
BRPI0313511-0A
Other languages
English (en)
Inventor
Eric Blasko
Katalin Kauser
John Parkinson
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0313511A publication Critical patent/BR0313511A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C12N9/0075—Nitric-oxide synthase (1.14.13.39)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

"eNOS MUTANTES úTEIS PARA A TERAPIA DE GENES". A presente invenção proporciona polipeptídios mutantes do ácido nítrico da sintase endotelial (eNOS), e polinucleotídios que codificam esses polipeptídios mutantes, úteis para a terapia de genes. De modo específico, a invenção proporciona polipeptídios eNOS mutantes que tenham uma ou mais mutações em uma seqüência de amino ácidos que corresponda a um domínio funcional de um eNOS de mamífero. De modo mais específico, a invenção provê polipeptídios eNOS mutantes que tenham pelo menos uma mutação em uma posição que corresponda a de um resíduo de amino ácido em um sítio de ligação da calmodulina que seja fosforilado em células de mamíferos, em que a mutação não é uma substituição de amino ácido para Ala ou Asp em um polipeptídio eNOS mutante que tenha uma única mutação que esteja no sítio de fosforilação; e a polinucleotídios que codificam esses peptídios mutantes. A presente invenção proporciona, ainda métodos profiláticos, diagnósticos e terapêuticos de utilização de tais polipeptídios e polinucleotídios eNOS mutantes.
BRPI0313511-0A 2002-08-16 2003-08-15 enos mutantes úteis para terapia de genes BR0313511A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40363802P 2002-08-16 2002-08-16
PCT/US2003/025745 WO2004016764A2 (en) 2002-08-16 2003-08-15 eNOS MUTANTS USEFUL FOR GENE THERAPY

Publications (1)

Publication Number Publication Date
BR0313511A true BR0313511A (pt) 2006-06-13

Family

ID=31888260

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0313511-0A BR0313511A (pt) 2002-08-16 2003-08-15 enos mutantes úteis para terapia de genes

Country Status (15)

Country Link
US (1) US20040096881A1 (pt)
EP (1) EP1553973A4 (pt)
JP (1) JP2005535345A (pt)
KR (1) KR20050042788A (pt)
CN (1) CN1691958A (pt)
AU (1) AU2003265461A1 (pt)
BR (1) BR0313511A (pt)
CA (1) CA2494847A1 (pt)
IL (1) IL166511A0 (pt)
MX (1) MXPA05001906A (pt)
NO (1) NO20051347L (pt)
PL (1) PL375219A1 (pt)
RU (1) RU2005107410A (pt)
WO (1) WO2004016764A2 (pt)
ZA (1) ZA200502183B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050074448A1 (en) * 2003-03-24 2005-04-07 The Curator Sof The University Of Missouri Method of treatment of endothelial dysfunction and engineered proteins for same
EP1708690B1 (en) 2003-11-17 2016-07-20 BioMarin Pharmaceutical Inc. Treatment of phenylketonuria with bh4
CA2842232C (en) 2005-03-10 2015-01-27 Gen-Probe Incorporated Systems and methods to perform assays for detecting or quantifying analytes within samples
US7739054B2 (en) * 2005-06-22 2010-06-15 Gen-Probe Incorporated Method and algorithm for quantifying polynucleotides
US10550178B2 (en) * 2010-03-18 2020-02-04 Srikanth Vedamoorthy Antibodies for detecting redox modulated proteins
US9439978B2 (en) 2011-09-29 2016-09-13 University Of South Florida Multilayered magnetic micelle compositions and methods for their use
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US9782494B2 (en) 2012-02-23 2017-10-10 University Of South Florida Methods of using multilayer magnetic micelle compositions
WO2013154771A1 (en) * 2012-04-12 2013-10-17 Georgia Regents University Redox-resistant nitric oxide synthase
CN106415562B (zh) * 2014-06-25 2019-12-10 国立研究开发法人科学技术振兴机构 膜蛋白质的热稳定化突变体预测装置、热稳定化突变体预测方法、以及程序
CN107802826B (zh) * 2017-10-26 2020-02-18 首都医科大学宣武医院 eNOS突变体在促进血管生成中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369764A1 (en) * 1999-04-16 2000-10-26 Yale University Enos mutations useful for gene therapy and therapeutic screening
US6620616B1 (en) * 2000-09-13 2003-09-16 The Cleveland Clinic Foundation Nucleic acids encoding nitric oxide synthase variants

Also Published As

Publication number Publication date
AU2003265461A1 (en) 2004-03-03
MXPA05001906A (es) 2005-04-28
EP1553973A2 (en) 2005-07-20
ZA200502183B (en) 2006-09-27
JP2005535345A (ja) 2005-11-24
EP1553973A4 (en) 2006-03-01
KR20050042788A (ko) 2005-05-10
NO20051347L (no) 2005-04-28
RU2005107410A (ru) 2006-01-20
PL375219A1 (en) 2005-11-28
CN1691958A (zh) 2005-11-02
IL166511A0 (en) 2006-01-15
WO2004016764A3 (en) 2005-05-19
US20040096881A1 (en) 2004-05-20
WO2004016764A2 (en) 2004-02-26
CA2494847A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
NO20051347L (no) eNOS-mutanter som er nyttige til genterapi.
Haney et al. Structural basis for thermostability and identification of potential active site residues for adenylate kinases from the archaeal genus Methanococcus
Bertrand et al. Crystal structure of UDP‐N‐acetylmuramoyl‐L‐alanine: D‐glutamate ligase from Escherichia coli
Hao et al. Mutation of phosphoserine 389 affects p53 function in vivo
Scaloni et al. Topology of the calmodulin-melittin complex
Niefind et al. Protein kinase CK2 in health and disease: Protein kinase CK2: from structures to insights
Warshel et al. Free energy of charges in solvated proteins: microscopic calculations using a reversible charging process
Cheng et al. Crystal structure of the Hhal DNA methyltransferase complexed with S-adenosyl-L-methionine
Liu et al. A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src
Callebaut et al. From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair
Sheriff et al. Influence of solvent accessibility and intermolecular contacts on atomic mobilities in hemerythrins.
Daniels et al. Conserved structural motifs governing the stoichiometric repair of alkylated DNA by O6-alkylguanine-DNA alkyltransferase
DK1295944T3 (da) GDP-dissociationsstimulerende protein, hjernespecifikt nukleosomsamlingsprotein, skeletmuskelspecifikt ubiquitinkonjugerende enzym, celleproliferationsprotein, phosphatidylinositolkinase, nelbeslægtede proteiner
Das et al. Functional significance and mechanism of eIF5-promoted GTP hydrolysis in eukaryotic translation initiation
WO1995011309A3 (en) A novel nuclear mitotic phosphoprotein: mitosin
Reardon et al. Thermodynamic cooperativity and kinetic proofreading in DNA damage recognition and repair
Weber et al. Computational and site‐specific mutagenesis analyses of the asymmetric charge distribution on calmodulin
Brady et al. Biochemical and functional diversity of microtubule motors in the nervous system
McDowell et al. Phosphorylation in intrinsically disordered regions regulates the activity of Neurogenin2
Lehman Hybrid troponin reconstituted from vertebrate and arthropod subunits
EP1005539A4 (en) IKK-ALPHA PROTEINS, NUCLEIC ACIDS AND METHOD
Hashimoto et al. Studies on the site in the regulatory subunit of type I cAMP-dependent protein kinase phosphorylated by cGMP-dependent protein kinase.
Dyer et al. Strategies for selecting mutation sites for methionine enhancement in the bean seed storage protein phaseolin
Siwiak et al. Structural models of CFTR–AMPK and CFTR–PKA interactions: R-domain flexibility is a key factor in CFTR regulation
Lin et al. Molecular analyses of an unusual translesion DNA polymerase from Methanosarcina acetivorans C2A

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010.